{"id":41371,"date":"2021-10-31T07:16:23","date_gmt":"2021-10-31T07:16:23","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=41371"},"modified":"2021-11-01T15:58:37","modified_gmt":"2021-11-01T15:58:37","slug":"durability-of-immune-responses-to-oxford-az-vaccine-in-hiv-positive-people","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/41371","title":{"rendered":"Durability of immune responses to COVID-19 vaccines in HIV positive people"},"content":{"rendered":"
\n

Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n

\n

<\/span><\/strong><\/p>\n<\/div>\n

\n

Extended follow-up from the HIV positive substudy in 54 HIV positive men reports that six months after vaccination with Oxford\/AstraZeneca ChAdOx1 vaccine, both humoral and cell mediated immunity decline. [1]<\/strong><\/p>\n

Similar declines were reported for HIV negative controls. Importantly, participants were all on suppressed ART with very high CD4 counts (median ~700 cells\/mm3<\/sup> (IQR: 573 to 859). Levels generally remained higher than before vaccination.<\/p>\n

Responses to the variants of concern were detectable, but lower than wild type.<\/p>\n

Two additional studies recently also reported on vaccines responses in people living with HIV. As with the Oxford above, both were in people with high median CD4 counts. [2, 3]<\/p>\n

These included n=143 and \u00a0n=121 HIV positive people, respectively.<\/p>\n

The first included just three people with CD4s <200 cells\/mm3<\/sup> who responded comparably to people with higher counts (but no overall correlation with CD4 counts is reported for the entire study population).<\/p>\n

The second study included six people with CD4 counts <250 cells\/mm3<\/sup> and reported significantly lower immunogenicity compared to other groups.<\/p>\n

References<\/p>\n

    \n
  1. Ogbe A el al. Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV – responses to SARS-CoV-2, variants of concern and circulating coronaviruses. Preprint. medRxiv\u00a02021.09.28.21264207.\u00a0doi: 10.1101\/2021.09.28.21264207.
    \nhttps:\/\/www.medrxiv.org\/content\/10.1101\/2021.09.28.21264207v1<\/a><\/li>\n
  2. Levy I et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clinical microbiology and infection. DOI: 10.1016\/j.cmi.2021.07.031. (23 August 2021).
    \n    https:\/\/www.clinicalmicrobiologyandinfection.com\/article\/S1198-743X(21)00423-7\/fulltext\u00a0<\/a><\/li>\n
  3. Nault L et al. Covid-19 vaccine immunogenicity in people living with HIV-1. Preprint article. (13 August 2021).
    \n    https:\/\/www.biorxiv.org\/content\/10.1101\/2021.08.13.456258v1<\/a><\/li>\n<\/ol>\n\n

    Ref: Ogbe \u00a0A el al. Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV – responses to SARS-CoV-2, variants of concern and circulating coronaviruses. Preprint. medRxiv\u00a02021.09.28.21264207.\u00a0doi: 10.1101\/2021.09.28.21264207.
    \n<\/span>    https:\/\/www.medrxiv.org\/content\/10.1101\/2021.09.28.21264207v1<\/a><\/p>\n

    This report was first published on 4 October 2021.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base Extended follow-up from the HIV positive substudy in 54 HIV positive men reports that six months after vaccination with Oxford\/AstraZeneca ChAdOx1 vaccine, both humoral and cell mediated immunity decline. [1] Similar declines were reported for HIV …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[292,278],"tags":[],"class_list":["post-41371","post","type-post","status-publish","format-standard","hentry","category-covid-19-vaccine","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/41371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=41371"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/41371\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=41371"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=41371"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=41371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}